Gavin Clark-Gartner
Stock Analyst at Evercore ISI
(4.94)
# 147
Out of 4,693 analysts
235
Total ratings
67.4%
Success rate
42.1%
Average return
Main Sectors:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Rated: Buy | $235 → $260 | $259.99 | +0.00% | 18 | Aug 10, 2026 | |
| SRPT Sarepta Therapeutics | Maintained: Hold | $19 | $21.33 | -10.92% | 28 | Aug 10, 2026 | |
| TVTX Travere Therapeutics | Rated: Buy | $68 → $78 | $65.71 | +18.70% | 9 | Aug 10, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintained: Buy | $33 | $25.81 | +27.86% | 5 | Aug 10, 2026 | |
| VRDN Viridian Therapeutics | Maintained: Buy | $26 | $23.03 | +12.90% | 12 | Aug 10, 2026 | |
| TENX Tenax Therapeutics | Downgraded: Hold | $39 → $5 | $1.80 | +177.78% | 2 | Aug 10, 2026 | |
| DNTH Dianthus Therapeutics | Maintained: Buy | $120 → $134 | $106.62 | +25.68% | 10 | Aug 10, 2026 | |
| CMPS COMPASS Pathways | Maintained: Buy | $21 | $13.24 | +58.61% | 6 | Aug 10, 2026 | |
| EVMN Evommune | Maintained: Buy | $55 → $22 | $12.48 | +76.28% | 4 | Aug 10, 2026 | |
| INSM Insmed | Maintained: Buy | $162 → $170 | $121.51 | +39.91% | 8 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $329 | $260.25 | +26.42% | 14 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1,059 | $1,028.51 | +2.96% | 13 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $33 | $25.10 | +31.47% | 7 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $91 | $34.23 | +165.85% | 8 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $88 → $85 | $84.95 | +0.06% | 6 | Jul 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.6976 | - | 8 | Jul 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $16.69 | - | 7 | Jul 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $35.28 | +44.56% | 1 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $126 → $138 | $98.34 | +40.33% | 19 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $295 → $300 | $363.84 | -17.55% | 14 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $18 | $14.19 | +26.85% | 4 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $46 | $28.14 | +63.47% | 1 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 → $26 | $38.50 | -32.47% | 5 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 → $17 | $9.92 | +71.37% | 4 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $2.12 | +135.85% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 | $3.73 | +34.05% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $1.20 | +233.33% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $3.30 | +21.21% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $18 | $5.69 | n/a | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $3.87 | n/a | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $78 | $125.01 | n/a | 1 | Aug 3, 2022 |
AbbVie
Aug 10, 2026
Rated: Buy
Price Target: $235 → $260
Current: $259.99
Upside: +0.00%
Sarepta Therapeutics
Aug 10, 2026
Maintained: Hold
Price Target: $19
Current: $21.33
Upside: -10.92%
Travere Therapeutics
Aug 10, 2026
Rated: Buy
Price Target: $68 → $78
Current: $65.71
Upside: +18.70%
Ultragenyx Pharmaceutical
Aug 10, 2026
Maintained: Buy
Price Target: $33
Current: $25.81
Upside: +27.86%
Viridian Therapeutics
Aug 10, 2026
Maintained: Buy
Price Target: $26
Current: $23.03
Upside: +12.90%
Tenax Therapeutics
Aug 10, 2026
Downgraded: Hold
Price Target: $39 → $5
Current: $1.80
Upside: +177.78%
Dianthus Therapeutics
Aug 10, 2026
Maintained: Buy
Price Target: $120 → $134
Current: $106.62
Upside: +25.68%
COMPASS Pathways
Aug 10, 2026
Maintained: Buy
Price Target: $21
Current: $13.24
Upside: +58.61%
Evommune
Aug 10, 2026
Maintained: Buy
Price Target: $55 → $22
Current: $12.48
Upside: +76.28%
Insmed
Aug 7, 2026
Maintained: Buy
Price Target: $162 → $170
Current: $121.51
Upside: +39.91%
Aug 7, 2026
Maintained: Buy
Price Target: $329
Current: $260.25
Upside: +26.42%
Jul 27, 2026
Maintained: Buy
Price Target: $1,059
Current: $1,028.51
Upside: +2.96%
Jul 27, 2026
Maintained: Buy
Price Target: $33
Current: $25.10
Upside: +31.47%
Jul 9, 2026
Maintained: Buy
Price Target: $91
Current: $34.23
Upside: +165.85%
Jul 8, 2026
Downgraded: Hold
Price Target: $88 → $85
Current: $84.95
Upside: +0.06%
Jul 6, 2026
Rated: Hold
Price Target: n/a
Current: $0.6976
Upside: -
Jul 6, 2026
Rated: Hold
Price Target: n/a
Current: $16.69
Upside: -
May 26, 2026
Initiated Coverage: Buy
Price Target: $51
Current: $35.28
Upside: +44.56%
May 7, 2026
Maintained: Buy
Price Target: $126 → $138
Current: $98.34
Upside: +40.33%
May 5, 2026
Maintained: Buy
Price Target: $295 → $300
Current: $363.84
Upside: -17.55%
Apr 1, 2026
Maintained: Buy
Price Target: $20 → $18
Current: $14.19
Upside: +26.85%
Mar 25, 2026
Initiated Coverage: Buy
Price Target: $46
Current: $28.14
Upside: +63.47%
Mar 2, 2026
Maintained: Buy
Price Target: $24 → $26
Current: $38.50
Upside: -32.47%
Feb 18, 2026
Initiated Coverage: Buy
Price Target: $8 → $17
Current: $9.92
Upside: +71.37%
Dec 17, 2025
Maintained: Buy
Price Target: $5
Current: $2.12
Upside: +135.85%
Dec 17, 2025
Maintained: Hold
Price Target: $5
Current: $3.73
Upside: +34.05%
Dec 17, 2025
Maintained: Hold
Price Target: $4
Current: $1.20
Upside: +233.33%
Dec 17, 2025
Maintained: Hold
Price Target: $4
Current: $3.30
Upside: +21.21%
Dec 20, 2024
Reiterated: Buy
Price Target: $20 → $18
Current: $5.69
Upside: n/a
May 30, 2023
Maintained: Buy
Price Target: $10
Current: $3.87
Upside: n/a
Aug 3, 2022
Downgraded: Hold
Price Target: $78
Current: $125.01
Upside: n/a